59,649 results match your criteria Renal Cell Carcinoma

Long non-coding RNA CYTOR modulates cancer progression through miR-136-5p/MAT2B axis in renal cell carcinoma.

Toxicol Appl Pharmacol 2022 May 18:116067. Epub 2022 May 18.

Department of Urology Surgery, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010050, China. Electronic address:

Background: To explore the role of long noncoding RNAs (lncRNAs) cytoskeleton regulator RNA (CYTOR) in renal cell carcinoma (RCC).

Methods: The levels of CYTOR in RCC tissues and cell lines were detected by RT-qPCR. 786-O and Caki-1 cells were transfected with CYTOR-shRNA or pcDNA-CYTOR respectively, or co-transfected with CYTOR-shRNA and miR-136-5p inhibitor, or co-transfected with miR-136-5p mimic and pcDNA-MAT2B. Read More

View Article and Full-Text PDF

The WHO 2022 landscape of papillary and chromophobe renal cell carcinoma.

Histopathology 2022 May 21. Epub 2022 May 21.

Department of Pathology and Molecular Pathology, University and University Hospital Zurich, Zurich, Switzerland.

The 5 edition of the WHO Classification of Tumours of the Urinary and Male Genital Systems contains relevant revisions and introduces a group of molecularly defined renal tumour subtypes. Herein we present the World Health Organization (WHO) 2022 perspectives on papillary and chromophobe renal cell carcinoma with emphasis on their evolving classification, differential diagnosis, and emerging entities. The WHO 2022 classification eliminated the type 1/2 papillary renal cell carcinoma (pRCC) subcategorization, given the recognition of frequent mixed tumour phenotypes and the existence of entities with different molecular background within the type 2 pRCC category. Read More

View Article and Full-Text PDF

Patient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer Agents.

Clin Genitourin Cancer 2022 Apr 25. Epub 2022 Apr 25.

Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill (UNC-CH), Chapel Hill, NC; Lineberger Comprehensive Cancer Center (LCCC), UNC-CH, Chapel Hill, NC, USA; Duke Cancer Institute (DCI), DUSM, Durham, NC, USA.

Purpose: In an era of rapid expansion of FDA approvals for oral anticancer agents (OAAs), it is important to understand the factors associated with survival among real-world populations, which include groups not well-represented in pivotal clinical trials of OAAs, such as the elderly, racial minorities, and medically complex patients. Our objective was to evaluate patient- and provider-level characteristics' associations with mortality among a multi-payer cohort of metastatic renal cell carcinoma (mRCC) patients who initiated OAAs.

Methods: This retrospective cohort study was conducted using data from the North Carolina state cancer registry linked to multi-payer claims data for the years 2004 to 2015. Read More

View Article and Full-Text PDF

High-Concentration Metformin Reduces Oxidative Stress Injury and Inhibits the Growth and Migration of Clear Cell Renal Cell Carcinoma.

Comput Math Methods Med 2022 10;2022:1466991. Epub 2022 May 10.

The Third Department of Endocrinology, Central Hospital of Cangzhou, China.

Objective: To explore the mechanism of metformin in treating .

Methods: Prospective cohort study was conducted. and in six samples donated by volunteers were detected to compare the degree of oxidative stress injury and the status of cell proliferation. Read More

View Article and Full-Text PDF

Integration of Tumor Microenvironment in Patient-Derived Organoid Models Help Define Precision Medicine of Renal Cell Carcinoma.

Front Immunol 2022 3;13:902060. Epub 2022 May 3.

Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Renal cell carcinoma (RCC) is a common urological tumor, with a poor prognosis, as the result of insensitivity to chemotherapy and radiotherapy. About 20%-30% of patients with RCC have metastasis at the first diagnosis, so only systemic treatment is possible. Due to the heterogeneity of renal tumors, responses to drugs differ from person to person. Read More

View Article and Full-Text PDF

Identification and Verification of mG Modification Patterns and Characterization of Tumor Microenvironment Infiltration Multi-Omics Analysis in Clear Cell Renal Cell Carcinoma.

Front Immunol 2022 3;13:874792. Epub 2022 May 3.

Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China.

The epigenetic modification of tumorigenesis and progression in neoplasm has been demonstrated in recent studies. Nevertheless, the underlying association of N7-methylguanosine (mG) regulation with molecular heterogeneity and tumor microenvironment (TME) in clear cell renal cell carcinoma (ccRCC) remains unknown. We explored the expression profiles and genetic variation features of mG regulators and identified their correlations with patient outcomes in pan-cancer. Read More

View Article and Full-Text PDF

A pilot study investigating the feasibility of using a fully automatic software to assess the RENAL and PADUA score.

Prog Urol 2022 May 16. Epub 2022 May 16.

Inserm U1065, C3M, Université Côte d'Azur, Nice, France; Department of Clinical Biochemistry, University Hospital of Nice, Nice, France; 3IA Institute, Université Côte d'Azur, France.

Purpose: Image-based morphometric scoring systems such as the RENAL and PADUA scores are useful to evaluate the complexity of partial nephrectomy for renal cell carcinoma (RCC). The main aim of this study was to develop a new imaging software to enable an automatic detection and a 3D visualization of RCC from CT angiography (CTA) and to address the feasibility to use it to evaluate the features of the RENAL and the PADUA scores.

Methods: A training dataset of 210 patients CTA-scans manually segmented was used to train a deep learning algorithm to develop the automatic detection and 3D-visualization of RCC. Read More

View Article and Full-Text PDF

The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications.

Pharmacol Res 2022 May 16;181:106261. Epub 2022 May 16.

First Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece; Basic and Translational Research Unit, Special Unit for Biomedical Research and Education, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece. Electronic address:

Hepatocellular carcinoma (HCC) occurs in the setting of prolonged liver inflammation, hepatocyte necrosis and regeneration in patients with cirrhosis. Despite the progress made in the medical management of the disorder during the past decades, the available pharmacological options remain limited, leading to poor survival rates and quality of life for patients with HCC. Sodium-glucose cotransporter 2 inhibitors (SGLT2) originally emerged as drugs for the treatment of hyperglycemia; however, they soon demonstrated important extra-glycemic properties, which led to their evaluation as potential treatments for a wide range of non-metabolic disorders. Read More

View Article and Full-Text PDF

Benchmarking weakly-supervised deep learning pipelines for whole slide classification in computational pathology.

Med Image Anal 2022 May 4;79:102474. Epub 2022 May 4.

Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany; Division of Pathology and Data Analytics, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK; Else Kroener Fresenius Center for Digital Health, Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany. Electronic address:

Artificial intelligence (AI) can extract visual information from histopathological slides and yield biological insight and clinical biomarkers. Whole slide images are cut into thousands of tiles and classification problems are often weakly-supervised: the ground truth is only known for the slide, not for every single tile. In classical weakly-supervised analysis pipelines, all tiles inherit the slide label while in multiple-instance learning (MIL), only bags of tiles inherit the label. Read More

View Article and Full-Text PDF

Novel Diagnostic Value of Driver Gene Transcription Signatures to Characterise Clear Cell Renal Cell Carcinoma, ccRCC.

Pathol Oncol Res 2022 2;28:1610345. Epub 2022 May 2.

Albert Szent-Györgyi Clinical Center, Albert Szent-Györgyi Medical School, Institute of Pathology, University of Szeged, Szeged, Hungary.

Routine molecular tumour diagnostics are augmented by DNA-based qualitative and quantitative molecular techniques detecting mutations of DNA. However, in the past decade, it has been unravelled that the phenotype of cancer, as it's an extremely complex disease, cannot be fully described and explained by single or multiple genetic variants affecting only the coding regions of the genes. Moreover, studying the manifestation of these somatic mutations and the altered transcription programming-driven by genomic rearrangements, dysregulation of DNA methylation and epigenetic landscape-standing behind the tumorigenesis and detecting these changes could provide a more detailed characterisation of the tumour phenotype. Read More

View Article and Full-Text PDF

PARG suppresses tumorigenesis and downregulates genes controlling angiogenesis, inflammatory response, and immune cell recruitment.

BMC Cancer 2022 May 18;22(1):557. Epub 2022 May 18.

Department of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND, 58202, USA.

Chemokines are highly expressed in tumor microenvironment and play a critical role in all aspects of tumorigenesis, including the recruitment of tumor-promoting immune cells, activation of cancer-associated fibroblasts, angiogenesis, metastasis, and growth. Poly (ADP-ribose) polymerase (PARP) is a multi-target transcription regulator with high levels of poly(ADP-ribose) (pADPr) being reported in a variety of cancers. Furthermore, poly (ADP-ribose) glycohydrolase (PARG), an enzyme that degrades pADPr, has been reported to be downregulated in tumor tissues with abnormally high levels of pADPr. Read More

View Article and Full-Text PDF

GTSE1 promotes tumor growth and metastasis by attenuating of KLF4 expression in clear cell renal cell carcinoma.

Lab Invest 2022 May 18. Epub 2022 May 18.

Department of Urology, the Third Medical Center, Chinese PLA General Hospital, Beijing, 100039, China.

Clear cell renal cell carcinoma (ccRCC) is one of the most common malignant tumors and is characterized by a poor prognosis. Although G2- and S -phase expressed-1 (GTSE1) is known to be involved in the progression and metastasis of various cancers, its significance and mechanism in ccRCC remain unknown. In the present study, we found that GTSE1 was overexpressed in ccRCC tissues, especially in metastatic samples. Read More

View Article and Full-Text PDF

Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry.

Clin Genitourin Cancer 2022 Apr 9. Epub 2022 Apr 9.

Department of Urology, UC San Diego School of Medicine, La Jolla, CA. Electronic address:

Background: Treatment paradigms for management of metastatic renal cell carcinoma (mRCC) are evolving. We examined impact of surgical metastasectomy on survival across in mRCC stratified by risk-group.

Methods: Multicenter retrospective analysis from the Registry of Metastatic RCC database. Read More

View Article and Full-Text PDF

Multiple organ dysfunction due to inferior vena cava thrombosis diagnosed by point-of-care ultrasound in the intensive care unit.

Issac Cheong

J Clin Ultrasound 2022 May 18. Epub 2022 May 18.

Department of Critical Care Medicine, Sanatorio De los Arcos, Buenos Aires, Argentina.

We describe the case of a 75-years-old woman with history of left renal cell carcinoma that presented multiple organ dysfunction due to IVCT diagnosed by point-of-care ultrasound (POCUS) in the intensive care unit (ICU). Read More

View Article and Full-Text PDF

CHMP1A suppresses the growth of renal cell carcinoma cells via regulation of the PI3K/mTOR/p53 signaling pathway.

Genes Genomics 2022 May 18. Epub 2022 May 18.

School of Food Science and Engineering, Hangzhou Medical College, Hangzhou, Zhejiang, China.

Background: CHMP1A, a member of the ESCRT-III complex family, has been indicated as a brand-new inhibitor gene of tumors. Our previous research has revealed that CHMP1A plays a vital role in the development and progression of renal cell carcinoma (RCC).

Objective: To investigate the potential target pathway of the regulation of the tumor cell growth by CHMP1A. Read More

View Article and Full-Text PDF

Glutaminase inhibition in renal cell carcinoma therapy.

Cancer Drug Resist 2019 19;2(2):356-364. Epub 2019 Jun 19.

School of Medicine, University of St Andrews, St Andrews KY16 9TF, UK.

Receptor tyrosine kinase inhibitors have been a standard first-line therapy for renal cell carcinoma (RCC) for over a decade. Although they stabilize the disease, they are unable to remove all tumor cells, leading to relapse. Moreover, both intrinsic and acquired resistance to therapy are a significant health burden. Read More

View Article and Full-Text PDF

Resistance to cancer immunotherapy in metastatic renal cell carcinoma.

Cancer Drug Resist 2020 2;3(3):454-471. Epub 2020 Jul 2.

Centre de Recherche des Cordeliers, INSERM, Université de Paris, Sorbonne Université, Paris F-75006, France.

The prognosis of metastatic clear cell renal cell carcinoma (mccRCC) has changed dramatically over the years with the emergence of immune checkpoint inhibitors (ICI) used alone, or in combination with another ICI, or with vascular endothelial growth factor receptor tyrosine kinase inhibitor. Although major response rates have been observed with ICI, many patients do not respond, reflecting primary resistance, and durable responses remain exceptional, reflecting secondary resistance. Factors contributing to primary and acquired resistance are manifold, including patient-intrinsic factors, tumor cell-intrinsic factors and factors associated with the tumoral microenvironment (TME). Read More

View Article and Full-Text PDF

Successful apatinib treatment for advanced clear cell renal carcinoma as a first-line palliative treatment: A case report.

World J Clin Cases 2022 Apr;10(11):3593-3600

Department of Medical Oncology, Dongyang Hospital Affiliated to Wenzhou Medical University, Dongyang 322100, Zhejiang Province, China.

Background: Apatinib is an orally bioavailable small-molecule receptor tyrosine kinase inhibitor. In December 2014, the China Food and Drug Administration made it the first anti-angiogenic therapy to be approved for treating metastatic gastric cancer. It was specifically designated as a third-line or later treatment for metastatic gastric cancer. Read More

View Article and Full-Text PDF

Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.

J Med Case Rep 2022 May 18;16(1):193. Epub 2022 May 18.

Department of Urology, Nagano Municipal Hospital, 1333-1, Tomitake, Nagano, Nagano, Japan.

Background: Collecting duct carcinoma and sarcomatoid renal cell carcinoma are tumors with poor prognosis. Immune checkpoint inhibitors have been established as the standard treatment for advanced renal cell carcinoma. Some cases of remission of collecting duct carcinoma and sarcomatoid renal cell carcinoma have been reported using immune checkpoint inhibitor interventions. Read More

View Article and Full-Text PDF

Transarterial chemoembolization of unresectable renal cell carcinoma with doxorubicin-loaded CalliSpheres drug-eluting beads.

Sci Rep 2022 May 17;12(1):8136. Epub 2022 May 17.

Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, No.1, East Jian She Road, Zhengzhou, 450052, China.

The safety and efficacy of drug-eluting beads transarterial chemoembolization (DEB-TACE) for unresectable renal cell carcinoma (RCC) still unknown. We aimed to assess the feasibility, safety and clinical efficacy of DEB-TACE with doxorubicin-loaded CalliSpheres beads (CB) in patients with unresectable RCC. Between 2016 and 2020, thirty-five patients with unresectable RCC underwent DEB-TACE with doxorubicin-loaded CB. Read More

View Article and Full-Text PDF

Isolated soft tissue mass of the finger as the first presentation of oligometastatic renal cell carcinoma.

BMJ Case Rep 2022 May 17;15(5). Epub 2022 May 17.

Department of Urology, Saint James's Hospital, Dublin, Ireland.

A man in his 70s was referred to plastic surgery with a suspected foreign body in the pulp of his right index finger. An excisional biopsy was performed for a presumed foreign body granuloma. Histology revealed metastatic renal cell carcinoma (mRCC). Read More

View Article and Full-Text PDF

Special issue "The advance of solid tumor research in China": Multi-omics analysis based on 1311 clear cell renal cell carcinoma samples identify a glycolysis signature associated with prognosis and treatment response.

Int J Cancer 2022 May 17. Epub 2022 May 17.

Department of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.

In clear cell renal cell carcinoma (ccRCC), glycolysis is enhanced mainly because of the increased expression of key enzymes in glycolysis. Hence, the discovery of new molecular biomarkers for glycolysis may help guide and establish a precise system of diagnosis and treatment for ccRCC. Expression profiles of 1079 tumor samples of ccRCC patients (including 311 patients treated with Everolimus or Nivolumab) were downloaded from public databases. Read More

View Article and Full-Text PDF

Multidisciplinary integrated care pathway for von Hippel-Lindau disease.

Cancer 2022 May 17. Epub 2022 May 17.

Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.

Background: Clinical pathways are care plans established to describe essential steps in the care of patients with a specific clinical problem. They translate (inter)national guidelines into local applicable protocols and clinical practice. The purpose of this article is to establish a multidisciplinary integrated care pathway for specialists and allied health care professionals in caring for individuals with von Hippel-Lindau (VHL) disease. Read More

View Article and Full-Text PDF

Application of Contrast-Enhanced Ultrasound and Bosniak Classification in the Diagnosis of Cystic Renal Masses.

Curr Med Imaging 2022 May 9. Epub 2022 May 9.

College of Traditional Chinese Medicine, Jiangxi University of Traditional Chinese Medicine, Nanchang 330006, China.

Background: The Bosniak classification system based on the contrast-enhanced computed tomography (CECT) is commonly used for the differential diagnosis of cystic renal masses. Contrast-enhanced ultrasound (CEUS) is a relatively novel technique, which has gradually played an important role in the diagnosis of cystic renal cell carcinoma (CRCC) due to its safety and lowest price.

Objective: To investigate the application value of CEUS and Bosniak classification in the diagnosis of cystic renal masses. Read More

View Article and Full-Text PDF

Physical Activity in Patients With Kidney Cancer: A Scoping Review.

Clin Genitourin Cancer 2022 Apr 21. Epub 2022 Apr 21.

Faculty of Kinesiology, Sport, and Recreation, College of Health Sciences, University of Alberta, Edmonton, Alberta, Canada. Electronic address:

Physical activity (PA) helps many cancer patients improve health-related fitness, treatment-related side effects, quality of life, and possibly survival; however, limited research has been conducted in patients with kidney cancer (KC). The aim of this scoping review focused on PA in patients with KC was to summarize current findings, delineate strengths and limitations, and provide key recommendations for future research. A scoping review was conducted and reported in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for scoping reviews guidelines. Read More

View Article and Full-Text PDF

Treatment Strategies in Metastatic Renal Cancer: Dose Titration in Clear Cell Renal Cell Carcinoma.

Eur Urol 2022 May 13. Epub 2022 May 13.

Edinburgh Cancer Centre, University of Edinburgh, Edinburgh, UK.

View Article and Full-Text PDF

Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial.

Clin Cancer Res 2022 May 16. Epub 2022 May 16.

The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Purpose: Glutaminase is a key enzyme that supports elevated dependency of tumors on glutamine-dependent biosynthesis of metabolic intermediates. Dual targeting of glucose and glutamine metabolism by the mTOR inhibitor everolimus plus the oral glutaminase inhibitor telaglenastat showed preclinical synergistic anticancer effects which translated to encouraging safety and efficacy findings in a phase 1 trial of 2L+ renal cell carcinoma (RCC). This study evaluated telaglenastat plus everolimus (TelaE) versus placebo plus everolimus (PboE) in patients with advanced/metastatic RCC (mRCC) in the 3L+ setting (NCT03163667). Read More

View Article and Full-Text PDF

Expression Of Bap1 In Clear Cell Renal Cell Carcinoma.

J Ayub Med Coll Abbottabad 2022 Apr-Jun;34(2):283-287

Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan.

Background: BAP1 (BRCA1 associated protein 1 on chromosome 3) is a commonly mutated gene in clear cell renal cell carcinoma. Aim of the study was to evaluate the prognostic significance of BAP1 by immunohistochemistry in clear cell renal cell carcinoma.

Methods: It was a descriptive case series in which data was retrospectively collected. Read More

View Article and Full-Text PDF

Leukocytoclastic Vasculitis Induced by Immune Checkpoint Inhibition in a Patient With Advanced Renal Cell Carcinoma.

Oncology (Williston Park) 2022 May;36(5):316-320

A Mexican woman, aged 60 years, presented with fevers and abdominal pain. She had initially presented to an outside emergency department with weakness, malaise, nausea, vomiting, tachycardia to 110s, and fever to 102 °F. Her medical history was relevant for hypertension, prediabetes, and tobacco use (4-5 cigarettes/day for 12 years). Read More

View Article and Full-Text PDF

Association of Adjuvant or Metastatic Setting With Discontinuation of Cancer Drugs in Clinical Trials.

JAMA Netw Open 2022 May 2;5(5):e2212327. Epub 2022 May 2.

Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco.

Importance: Adjuvant drugs are used to reduce the risk of tumor recurrence in patients with cancer who are successfully treated with first-line therapy. The same drugs used in the metastatic or first-line setting are often used in the adjuvant setting, and although the resulting adverse effects may be similar between the 2 settings, tolerability may be different.

Objective: To compare the discontinuation rates of drugs in the adjuvant setting and in the metastatic setting in clinical trials of cancer drugs. Read More

View Article and Full-Text PDF